3/13/23 18:30 | 3/3/23 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | S.d | -657 | 1.04 | 0 | -635 | -71 | 261 | D | | | | | | | | | | | | | | |
3/13/23 18:30 | 3/3/23 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | M.d | 471 | 0.8200 | 0 | 575 | | 261 | D | | | | | | | | | | | | | | |
3/13/23 17:10 | 3/3/23 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Narido Richard Clavano | CA | O | CFO | S.m | -29 | 1.00 | 0 | -29 | -27 | 78 | D | | | | | | | | | | | | | | |
3/13/23 17:09 | 3/3/23 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Collins Kevin Walter | CA | O | Chief Re | S.m | -74 | 0.6604 | 0 | -112 | -32 | 235 | D | | | | | | | | | | | | | | |
3/13/23 17:08 | 3/3/23 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Allen Anthony Joseph | CA | O | Chief Op | S | -8 | 1.00 | 0 | -8 | -6 | 137 | D | | | | | | | | | | | | | | |
2/21/23 12:38 | 2/16/23 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -1 | 0.2700 | 0 | -5 | -4 | 134 | D | | | | | | | | | | | | | | |
12/22/22 14:24 | 12/20/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Allen Anthony Joseph | CA | O | Chief Op | S | -1 | 0.1600 | 0 | -4 | -3 | 145 | D | | | | | | | | | | | | | | |
12/9/22 16:24 | 11/21/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Allen Anthony Joseph | CA | O | Chief Op | S | -11 | 0.3300 | 0 | -34 | -19 | 149 | D | | | | | | | | | | | | | | |
12/9/22 16:17 | 11/28/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -3 | 0.4200 | 0 | -8 | -5 | 139 | D | | | | | | | | | | | | | | |
12/9/22 16:15 | 11/17/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -12 | 0.3724 | 0 | -33 | -18 | 147 | D | | | | | | | | | | | | | | |
12/6/22 16:21 | 12/1/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Narido Richard Clavano | CA | O | Interim | S | -1 | 0.3600 | 0 | -2 | -1 | 107 | D | | | | | | | | | | | | | | |
11/29/22 12:08 | 11/27/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Collins Kevin Walter | CA | O | Chief Re | S | -4 | 0.4200 | 0 | -10 | -3 | 347 | D | | | | | | | | | | | | | | |
11/18/22 20:05 | 11/16/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -2 | 0.3500 | 0 | -5 | -3 | 180 | D | | | | | | | | | | | | | | |
9/22/22 17:13 | 9/20/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Allen Anthony Joseph | CA | O | Chief Op | S | -24 | 1.39 | 0 | -17 | -8 | 184 | D | | | | | | | | | | | | | | |
9/20/22 17:30 | 9/18/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | George Dan | CA | O | CFO,Trea | S | 0 | 1.38 | 0 | 0 | -1 | 46 | D | | | | | | | | | | | | | | |
9/19/22 14:34 | 9/15/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | P | 36 | 1.82 | 0 | 20 | 7 | 321 | D | | | | | | | | | | | | | | |
9/6/22 20:48 | 9/1/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Mitra Debkishore | CA | DO | CTO | S | 0 | 1.69 | 0 | 0 | 0 | 382 | D | | | | | | | | | | | | | | |
8/29/22 20:22 | 8/27/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Collins Kevin Walter | CA | O | Chief Re | S | -15 | 1.72 | 0 | -9 | -2 | 356 | D | | | | | | | | | | | | | | |
8/29/22 20:19 | 8/25/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -3 | 1.93 | 0 | -2 | -1 | 185 | D | | | | | | | | | | | | | | |
8/24/22 15:54 | 8/17/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S.a | -48 | 2.52 | 0 | -19 | -10 | 181 | D | | | | | | | | | | | | | | |
8/19/22 21:40 | 8/17/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S.m | -62 | 2.74 | 0 | -23 | -11 | 177 | D | | | | | | | | | | | | | | |
7/12/22 18:27 | 3/1/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Mitra Debkishore | CA | DO | CTO | S.m | -5 | 4.19 | 0 | -1 | 0 | 382 | D | | | | | | | | | | | | | | |
7/12/22 18:25 | 3/1/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Prashar Tamanna | CA | O | VP | S.m | -7 | 3.98 | 0 | -2 | -2 | 117 | D | | | | | | | | | | | | | | |
7/12/22 18:24 | 5/27/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Collins Kevin Walter | CA | O | Chief Re | S | -74 | 2.00 | 0 | -37 | -9 | 365 | D | | | | | | | | | | | | | | |
7/12/22 18:22 | 6/18/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | George Dan | CA | O | CFO,Trea | S | -2 | 1.45 | 0 | -1 | -3 | 46 | D | | | | | | | | | | | | | | |
6/17/22 18:45 | 6/16/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | P | 15 | 1.49 | 0 | 10 | 3 | 301 | D | | | | | | | | | | | | | | |
3/16/22 18:47 | 3/15/22 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | P | 90 | 3.00 | 0 | 30 | 11 | 291 | D | | | | | | | | | | | | | | |
2/14/22 17:52 | 6/9/21 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Prashar Tamanna | CA | O | VP | M.d | 99 | 0.9558 | 0 | 104 | 904 | 115 | D | | | | | | | | | | | | | | |
2/9/21 18:39 | 2/5/21 | LHDX | Health | Diagn | In Vitro & In Vivo Diagnostic | Epiq Capital Group, LLC | CA | T | | P.d | 58,850 | 17.00 | 0 | 3,462 | New | 3,462 | D | | | | | | | | | | | | | | |